The challenge is particularly acute in medical technology, where sales cycles stretch 12-18 months, regulatory complexity demands cross-functional leadership, and the talent pool of VPs with hospital system relationships and FDA experience remains highly competitive. The right compensation structure doesn't just attract the candidate—it aligns incentives with the company's stage, reinforces strategic priorities, and retains leadership through critical growth phases.
This guide breaks down how to design VP of Sales compensation plans that work in 2026, from base salary benchmarks and variable pay structures to equity grants and performance metrics tailored for MedTech realities.
Key Takeaways
- Blend base (typically 60-70% of target) with variable pay, equity for retention, and strategic bonuses
- Early-stage firms weight variable pay higher; mature orgs favor base-heavy packages with equity refreshers
- Tie payouts to 3-5 KPIs: ARR growth, team quota attainment, pipeline health, and strategic milestones
- MedTech plans should reward pipeline development and cross-functional leadership, not revenue alone
What Makes a Strong VP of Sales Compensation Plan?
A strong VP compensation plan achieves three things simultaneously: it aligns the VP's financial success with company revenue growth, incentivizes team performance and development, and creates long-term commitment through equity or deferred value. Weak plans treat the VP like an individual contributor with a bigger title. Strong plans recognize the role's strategic leadership responsibilities (building process, managing forecasts, recruiting talent, and entering new markets) and reward accordingly.
Balance risk and reward by company stage. Pay mix should match cash constraints and growth risk:
- Early-stage: 50/50 base-to-variable with meaningful equity; conserves cash and offers significant upside for candidates betting on the trajectory
- Growth-stage: 60/40 or 70/30 as operational complexity rises and income needs to be more predictable
- Mature: 70/30 or 80/20 with smaller equity grants but larger absolute dollar compensation
Create transparency through clear payout mechanics. Ambiguity kills trust. Every component (base, variable, equity, bonuses) should have defined triggers, calculation formulas, and payout examples. A VP should be able to calculate their earnings at any quota attainment level without guessing. Clear mechanics also cut disputes and keep incentives pointed at the right behaviors.
Align incentives with strategic priorities, not just revenue. Revenue is necessary but insufficient. Tie variable pay to the outcomes that matter most right now:
- Breaking into hospital systems → reward new account wins
- Scaling the team → include hiring and ramp metrics
- Protecting retention → add net revenue retention to the scorecard
The plan should drive long-term success, not only short-term bookings.
Core Components of VP Sales Compensation
Base Salary: The Foundation
Base salary provides financial stability and acknowledges that a VP of Sales does far more than close deals. They hire teams, build scalable processes, manage forecasts, align cross-functionally with product and marketing, and represent the commercial strategy to executives and investors. Base salary compensates these leadership responsibilities.
Benchmark ranges vary by stage and geography. According to Salary.com's July 2026 data, the national average base salary for U.S. VPs of Sales is $225,080, with a 10th-to-90th percentile range of $194,631 to $259,380. Built In reports a slightly lower average base of $207,284 for tech-focused VP roles, reflecting industry mix.
These are general benchmarks. MedTech companies should adjust for industry complexity and candidate specialization.
Stage-based expectations (directional):
- Early-stage (Seed to Series A): Base salaries often fall in the $140K-$180K range as cash is tight and equity compensates for lower base
- Growth-stage (Series B-C): Base typically rises to $180K-$220K as the company scales and operational demands increase
- Late-stage/enterprise: Base can reach $220K-$300K or higher, reflecting market maturity, larger teams, and reduced risk
Base salary's proportion of total compensation increases with company maturity, reflecting lower financial risk and greater process complexity as the organization grows.
Variable Pay & Commission Structure
Variable pay is the performance-linked portion tied to revenue achievement, team quota attainment, and strategic milestones. It typically represents 30-50% of on-target earnings (OTE). OTE equals base salary plus target variable compensation assuming 100% goal achievement.
Common structures include:
- Quarterly or annual bonuses based on revenue targets
- Commission on team performance rather than individual deals
- Accelerators that reward overperformance (for example, 125% payout at 125% of quota)
- Stretch goals with significant upside for exceptional results
Most high-performing plans are uncapped. Caps signal you don't want your VP maximizing results and often encourage sandbagging or cause top performers to leave once they hit the ceiling. Monthly or quarterly payouts maintain motivation better than annual lump sums, providing regular feedback and cash flow visibility.
Pay-mix guidance: WorldatWork's 2025 case study documented a 60/40 base-to-variable split for a core sales role. Built In's 2026 aggregate data implies roughly 59% base and 41% additional cash for VP of Sales roles. Alexander Group puts most direct B2B sales roles between 60/40 and 70/30.
The right mix depends on your company's stage, risk appetite, and candidate profile.
Equity & Long-Term Incentives
Equity aligns the VP with long-term outcomes and supports retention. Early-stage companies typically offer stock options; later-stage and public companies use restricted stock units (RSUs).
Carta's 2026 data shows VC-backed VPs receive a median initial equity grant of 0.17%, while SVPs receive 0.36%. These are cross-functional benchmarks. Sales VPs may land in this range or slightly lower—Index Ventures notes VP Sales roles often get less equity than other VPs because commissions already make up a large share of total pay.
Standard vesting schedules follow a four-year vest with a one-year cliff. According to Carta, at least 95% of equity cliffs hit at the one-year mark. That structure keeps the VP committed through critical growth phases instead of walking away after a few months.
Refresher grants help retain high performers after the initial grant is largely vested or the company's valuation has climbed significantly.
Equity ranges (directional):
- Series A VPs: Historically 0.3%-0.8% (Index Ventures)
- Series B VPs: Historically 0.2%-0.7% (Index Ventures)
- Later-stage VPs: Often 0.25%-0.5%, though current medians fall below these ranges
Companies should benchmark equity against peer organizations at similar stages, valuation, and funding levels.
Performance Bonuses Beyond Revenue
Strategic bonuses reward initiatives that don't tie directly to revenue but drive long-term value. These can be structured quarterly or annually and may include multipliers for exceptional achievement.
Examples of strategic bonus triggers:
- Launching a new go-to-market motion (such as a partner channel or inside sales team)
- Successfully entering new geographic markets or therapeutic areas
- Hitting team development milestones: hiring and ramping 10 AEs to 80%+ quota attainment within 12 months
- Implementing a new sales methodology or CRM system that improves forecast accuracy
These bonuses recognize the reality that a VP's impact extends far beyond closed deals. Building a high-performing team from scratch, for instance, may take 6-12 months before revenue shows up, but it is foundational to scaling.
Three Proven VP Sales Compensation Models for 2026
The right mix of base, variable, and equity depends on company stage, risk tolerance, and growth goals. These three models cover the structures MedTech and growth companies use most often for VP Sales roles in 2026.
Model 1: The 50/50/25+ Startup Plan
The 50/50/25+ plan splits base and variable compensation evenly. Uncapped accelerators can push total earnings 25% or more above OTE when stretch goals are exceeded.
This structure suits aggressive growth-stage companies with high risk tolerance. It appeals to confident, high-performing VPs willing to bet on the company's trajectory.
Example structure:
- $300K OTE = $150K base + $150K variable
- 25% kicker activates when stretch revenue targets (such as 125% of plan) are achieved
- At 150% quota attainment, total cash could reach $375K+
This model works best when the company has strong product-market fit, a defined sales playbook, and needs a VP to execute aggressively rather than build infrastructure from scratch.
Model 2: The 70/30 Growth-Stage Plan with Equity
The 70/30 structure provides more stability while keeping strong performance incentives. It fits Series B or C companies that need to balance growth with operational discipline.
Meaningful equity grants vest against milestones such as regional expansion, revenue thresholds, or team-building goals.
Example structure:
- $350K OTE = $245K base + $105K variable
- Equity grant: 0.3%–0.5% vesting over four years
- Additional milestone-based equity for hitting expansion targets
This model attracts experienced VPs who value predictability and focus on building scalable processes rather than pure growth-at-all-costs execution. It suits companies moving from founder-led sales to professionalized commercial operations.
Model 3: Year-over-Year Growth Model for Mature Companies
This model ties variable pay to YoY improvements in ARR, net revenue retention, or gross profit rather than absolute quota numbers. It rewards sustainable, compound growth and strategic execution over short-term deal-making.
That makes it a strong fit for established companies with multi-year track records.
Example structure:
- $400K OTE = $280K base + $120K variable
- Hitting 20% YoY ARR growth unlocks 100% of variable target
- Accelerators for exceeding thresholds (for example, 150% payout at 30% YoY growth)
- Potential equity refreshers tied to multi-year performance
This approach aligns VP incentives with the board's focus on sustainable growth rather than volatile quarter-to-quarter swings. It is common in late-stage private and public companies where strategic execution and retention matter more than rapid land-grabs.
How to Design Your VP Sales Compensation Plan: Step-by-Step Framework
Step 1: Define your sales strategy and growth goals. Clarify whether you need aggressive market capture, strategic expansion into new segments, team building from scratch, or process optimization. A company entering its first hospital system requires different VP behaviors than one scaling a proven motion across 50 reps. Your compensation structure should reinforce the specific outcomes you need.
Step 2: Choose your compensation mix based on company stage and risk profile. Match base/variable split and equity to cash constraints and risk tolerance:
- Early-stage: 50/50 splits with higher equity to conserve cash and attract risk-tolerant leaders
- Growth-stage: 60/40 or 70/30 ratios that balance upside with stability
- Mature: 70/30 or 80/20 with RSUs—smaller equity percentages, higher absolute dollars
Step 3: Set 3-5 clear, measurable KPIs the VP can directly influence. Too many metrics create confusion; too few create tunnel vision. Strong KPI sets often include:
- Revenue or ARR growth
- Team quota attainment percentage
- Pipeline coverage ratio (3x or higher)
- Sales cycle length
- Net revenue retention (for expansion-focused roles)
Avoid subjective metrics that create disputes.
Step 4: Benchmark against industry standards. Use compensation data from executive recruiters, peer companies at similar stages, and industry reports. Adjust for geography, team size, and operational complexity.
Resources like Pave, Carta, and specialized MedTech recruiters like FloodGate Medical can provide stage-specific benchmarks. That data helps you structure competitive offers that reflect regulatory complexity and specialized talent requirements.
Step 5: Document everything in a clear commission agreement. Spell out:
- Payout mechanics
- KPI definitions
- Calculation examples
- Vesting schedules
- Quarterly review triggers
Revisit the plan as company strategy evolves. Fast-growing companies should review at least quarterly; every company should review annually, or sooner when funding, GTM strategy, or market conditions change significantly.
MedTech-Specific Compensation Considerations
MedTech sales cycles are significantly longer than SaaS. Bessemer Venture Partners' 2024 health-tech report identifies 12-18 months as the traditional healthcare sales benchmark, and MedReps notes that capital-equipment cycles often run from several months to over a year.
Compensation structures must account for this timing. Build in pipeline metrics alongside closed revenue so VPs aren't penalized for industry-standard cycle length.
Regulatory complexity elevates the role. Medical device sales require navigating FDA regulations, clinical validation requirements, and quality system compliance. The VP Sales role often extends beyond pure commercial execution to include cross-functional leadership with regulatory, clinical, and quality teams. That broader scope may warrant higher base pay than general B2B sales roles.
The talent pool is specialized and competitive. Premium packages go to VPs who bring:
- FDA approval experience
- Established hospital system relationships
- Therapeutic area expertise (interventional cardiology, oncology, robotics)
MedReps reported medical devices at 50.1% of postings in 2024 and 44.7% in 2025, with March 2026 postings up 14.1% month over month. Companies competing for this talent need competitive packages. Specialized MedTech recruiters can help structure offers around regulatory experience, clinical credibility, and strategic account relationships.
Common Mistakes to Avoid When Structuring VP Comp Plans
Mistake 1: Unrealistic quotas or too many KPIs
Overloading a plan with 8–10 metrics creates confusion and dilutes focus. WorldatWork's 2025 technology case study emphasized reducing plans to one to three primary measures aligned with revenue.
Unrealistic targets demotivate strong performers and encourage sandbagging. Keep primary metrics few, meaningful, and achievable—with clear thresholds.
Mistake 2: Capping commission potential
Caps signal you don't want your VP to maximize results. They often backfire: VPs push deals into the next period once they hit the ceiling, or top performers leave for uncapped roles.
If a cap is unavoidable for budget reasons, set it so only extraordinary overperformance triggers it. Consider one-time bonuses for results beyond the cap.
Mistake 3: Lacking transparency in payout mechanics
Ambiguous formulas, subjective metrics, or unclear definitions create distrust and disputes. Every component (base, variable, equity, bonuses) needs clear calculation methods, payout examples, and documentation.
A VP should be able to model pay at any performance level without guessing or waiting on finance to explain it.
Frequently Asked Questions
What is a good sales compensation plan for a VP of Sales?
A good plan balances competitive base (typically 60-70% of OTE) with variable pay tied to revenue and team metrics, plus equity for long-term alignment. Payout math should be fully transparent and reward the behaviors that matter most at your stage: growth, team building, or market entry.
What is the typical OTE for a VP of Sales in 2026?
Built In's 2026 data puts average U.S. VP of Sales total compensation at about $350,198, with OTE typically ranging from $250K-$450K by stage, industry, and geography. Early-stage roles often land at $250K-$300K; late-stage or enterprise roles reach $350K-$450K+, and specialized MedTech experience can command a premium.
What is the best base to variable ratio for VP of Sales compensation?
The most common splits are 60/40 or 70/30 (base to variable). Growth-stage companies often push 50/50 for upside; mature orgs lean 70/30 or 80/20 for stability. Built In's 2026 data implies roughly 59% base / 41% variable in aggregate—choose based on stage, risk appetite, and candidate preference.
How much equity should a VP of Sales receive?
Carta's 2026 data shows a median initial grant of 0.17% for VC-backed VPs (0.36% for SVPs). Index Ventures ranges put Series A VPs around 0.3%-0.8% and Series B around 0.2%-0.7%, with VP Sales often on the lower end because cash variable is already high. Grants typically vest over four years with a one-year cliff; refreshers help retain top performers.
What metrics should drive VP of Sales compensation?
Use 3-5 core metrics: ARR or net new revenue, team quota attainment, pipeline coverage (often 3x+), sales cycle length when speed matters, and net revenue retention if the VP owns expansion. In MedTech, add pipeline-building or strategic account penetration to reflect long cycles and hospital-system selling.
How often should VP Sales compensation plans be reviewed?
Review at least quarterly at fast-growing companies and annually at minimum everywhere else. Trigger an immediate review after funding rounds, major GTM shifts (new channel or market), or material market changes such as regulatory moves or competitive disruption.
